# Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

> **NCT06722183** · PHASE2 · RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 33 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Futibatinib orally administered
- **DRUG:** Tislelizumab (i.v. 200mg)

## Key facts

- **NCT ID:** NCT06722183
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06722183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06722183, "Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06722183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*